Plain-English translation of NCT06469593 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing automated insulin delivery (AID) systems — devices that automatically adjust insulin doses based on your blood sugar levels — to see if they can improve sleep quality and reduce cardiovascular risk factors in people with type 1 diabetes. Researchers want to compare the new treatment to standard care (injections or older pump systems) to understand whether the medication offers real benefits beyond just better blood sugar control.
People with type 1 diabetes often struggle with poor sleep and have higher risk of heart disease. Researchers believe that the newer, more automated insulin systems might reduce these risks by keeping blood sugar more stable around the clock, but this hasn't been thoroughly studied yet.
You likely qualify if…
You likely don't qualify if…
If you are selected, you will be randomly assigned to either start using an automated insulin delivery system right away or continue with your current treatment for 4 months. During this time, you will visit the clinic at baseline and after 4 months for detailed testing — including blood and urine samples, sleep monitoring at home, heart rate measurements, blood pressure tracking, and questionnaires about how you're feeling. You'll also have brief virtual check-ins at weeks 1, 5, and 9. In total, the active study phase lasts about 4 months.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Denmark